Treatment of hepatitis C in special populations

Clin Liver Dis. 2006 Nov;10(4):851-65. doi: 10.1016/j.cld.2006.08.001.

Abstract

Hepatitis C virus (HCV) is a major cause of liver disease worldwide and is the most common chronic blood-borne infection in the United States. Experience has shown that the epidemiology and the response to treatment of HCV vary in certain patient groups. Differences have been observed in people from different racial and ethnic groups and in patients who have HIV and end-stage renal disease. These groups generally were not included in the early large clinical trials of HCV treatment. This article reviews recent findings in these patients groups and examines future directions.

Publication types

  • Review

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Asian*
  • Black or African American*
  • HIV Infections / complications
  • Hepacivirus / growth & development*
  • Hepatitis C / complications
  • Hepatitis C / drug therapy*
  • Hepatitis C / ethnology*
  • Hepatitis C / virology
  • Hispanic or Latino*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Kidney Failure, Chronic / complications
  • Middle Aged
  • Polyethylene Glycols / therapeutic use
  • Recombinant Proteins
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a